Genotype specific peripheral lipid profile changes with hepatitis C therapy

Table 1 Baseline demographics n (%)

	All	Genotype 1	Genotype 2	Genotype 3	P value
Number of patients	321 (100)	232 (72.3)	58 (18.1)	31 (9.7)
Age (yr)	57.7 ± 10.3	58.9 ± 9.5	55.5 ± 12.1	54.6 ± 10.8	0.009
Gender (male)	221 (68.8)	160 (59.4)	41 (61.2)	20 (64.5)	0.845
Ethnicity
Caucasian	229 (71.3)	171 (73.7)	40 (70.0)	18 (58.1)	0.018
African American	19 (5.9)	18 (7.8)	1 (1.7)	0 (0.0)
Hispanic	55 (17.1)	32 (13.8)	13 (22.4)	10 (32.3)
Asian	16 (5.0)	9 (3.9)	4 (6.9)	3 (9.7)
Other	2 (0.6)	2 (0.9)	0 (0.0)	0 (0.0)
Diabetes	79 (24.6)	59 (25.4)	14 (24.2)	6 (19.4)	0.593
Hypertension	132 (41.1)	105 (45.3)	22 (37.9)	5 (16.1)	0.086
Hyperlipidemia	59 (18.4)	44 (19.0)	12 (20.7)	3 (9.7)	0.453
Cirrhotic	150 (46.7)	103 (44.4)	33 (56.9)	14 (45.2)	< 0.001
Treatment
IFN + SOF + RBV		25 (10.8)	0 (0.0)	0 (0.0)
SOF + RBV		57 (24.6)	58 (100)	31 (100)
SOF + SMV		42 (19.0)	0 (0.0)	0 (0.0)
SOF + LDV		140 (60.3)	0 (0.0)	0 (0.0)

IFN: Pegylated interferon; SOF: Sofosbuvir; RBV: Ribavirin; SMV: Simeprevir; LDV: Ledipasvir.

Table 2 Changes in liver function tests

	Genotype 1			Genotype 2			Genotype 3
	Start Tx	End Tx	P value	Start Tx	End Tx	P value	Start Tx	End Tx	P value
Albumin (g/dL)	3.5 ± 0.6	3.8 ± 0.6	< 0.001	3.5 ± 0.5	3.7 ± 0.6	< 0.002	3.4 ± 0.5	3.7 ± 0.6	< 0.001
ALT (U/L)	70.2 ± 58.3	31.7 ± 38.7	< 0.001	68.7 ± 48.3	26.4 ± 17.8	< 0.001	101.9 ± 61.6	30.7 ± 30.3	< 0.001
Total Bilirubin (mg/dL)	1.0 ± 0.8	0.9 ± 0.8	0.008	1.0 ± 0.9	0.9 ± 0.9	0.202	1.1 ± 0.7	1.1 ± 0.8	0.904
INR	1.1 ± 0.2	1.1 ± 0.3	0.112	1.1 ± 0.1	1.0 ± 0.1	< 0.001	1.1 ± 0.2	1.1 ± 0.3	0.509

ALT: Alanine transaminase; INR: International Normalized Ratio.

Table 3 Changes in lipid profile by genotype in patients with cirrhosis and non cirrhosis

	Total population			Non-cirrhotics			Cirrhotics
	Start Tx	End Tx	P value	Start Tx	End Tx	P value	Start Tx	End Tx	P value
Genotype 1
T Chol	156.9 ± 36.4	162.2 ± 41.0	0.005	169.9 ± 33.2	175.7 ± 38.2	0.046	146.4 ± 35.6	151.4 ± 40.0	0.052
HDL	51.6 ± 18.5	63.9 ± 32.8	< 0.001	54.4 ± 19.5	72.7 ± 36.4	< 0.001	49.3 ± 17.2	56.9 ± 27.6	0.002
LDL	80.2 ± 28.8	87.6 ± 62.7	0.058	87.1 ± 28.1	91.8 ± 31.6	0.091	74.6 ± 28.2	84.2 ± 79.1	0.15
TG	114.6 ± 56.0	108.7 ± 56.0	0.044	117.3 ± 55.1	111.6 ± 57.6	0.27	112.5 ± 56.6	106.4 ± 56.5	0.070
Genotype 2
T Chol	162.9 ± 35.8	163.0 ± 32.9	0.99	174.2 ± 29.8	173.7 ± 27.5	0.91	148.2 ± 37.7	148.9 ± 34.1	0.90
HDL	52.8 ± 18.6	54.8 ± 20.0	0.39	54.9 ± 17.4	55.3 ± 17.4	0.88	50.0 ± 19.7	54.0 ± 23.0	0.28
LDL	86.7 ± 34.0	87.4 ± 30.2	0.82	95.3 ± 31.8	96.4 ± 27.0	0.82	75.4 ± 33.4	75.7 ± 30.0	0.93
TG	114.3 ± 64.1	112.4 ± 65.8	0.73	120.6 ± 68.4	124.0 ± 74.2	0.72	106.1 ± 59.7	97.1 ± 48.6	0.078
Genotype 3
T Chol	141.5 ± 38.4	157.6 ± 34.4	< 0.001	161.4 ± 35.5	181.5 ± 23.5	0.001	125.1 ± 32.5	137.9 ± 29.1	0.025
HDL	45.4 ± 15.1	53.3 ± 16.6	0.038	49.3 ± 14.0	53.2 ± 14.3	0.37	42.2 ± 15.3	53.3 ± 18.2	0.065
LDL	81.4 ± 32.1	93.9 ± 34.9	< 0.001	92.5 ± 26.1	110.4 ± 21.4	0.003	72.2 ± 33.6	80.3 ± 37.9	0.045
TG	108.6 ± 47.5	98.8 ± 41.2	0.047	119.0 ± 58.6	112.6 ± 47.1	0.36	100.1 ± 33.4	87.5 ± 31.2	0.12

All values expressed as mean ± SD. All units are in mg/dL. T Chol: Total cholesterol; HDL: High density lipoprotein; LDL: Low density lipoprotein; TG: Triglycerides; Start Tx: Prior to treatment; End Tx: End of treatment.

Table 4 Differential effect in lipid profile by genotype in patients with cirrhosis and non-cirrhosis

	All patients				Non-cirrhotics				Cirrhotics
	GT1	GT2	GT3	P value	GT1	GT2	GT3	P value	GT1	GT2	GT3	P value
T Chol	5.3	0.1	16.1	0.017	5.8	-0.4	12.8	0.066	5.0	0.7	20.1	0.39
HDL	12.3	2.0	7.9	0.049	18.2	0.5	11.1	0.008	7.6	4.0	4.0	0.69
LDL	-5.9	-1.1	-11.9	0.550	4.6	1.0	8.1	0.150	9.7	0.3	17.9	0.82
TG	7.4	2.1	21.2	0.130	-5.7	3.4	-12.6	0.650	-6.1	-9.0	-6.4	0.76

All values expressed as mean ± SD. All units are in mg/dL. T Chol: Total cholesterol; HDL: High density lipoprotein; LDL: Low density lipoprotein; TG: Triglycerides; Start Tx: Prior to treatment; End Tx: End of treatment.